Anan Keisuke, Kawamura Kodai, Suga Moritaka, Ichikado Kazuya
Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
J Thorac Dis. 2018 Oct;10(10):5796-5803. doi: 10.21037/jtd.2018.09.73.
Although acute respiratory distress syndrome (ARDS) reportedly shows various clinical phenotypes with different risk and prognostic factors, few studies have assessed the clinical features and prognosis of pulmonary and extrapulmonary ARDS. The aim of the present study was to investigate clinical differences between pulmonary and extrapulmonary ARDS.
In total, 200 patients who met the Berlin criteria and were diagnosed with ARDS between October 2004 and September 2017 were included. We classified the patients into pulmonary and extrapulmonary ARDS groups. Both groups were assessed for 60-day mortality, duration of ventilation, and other clinical features.
There were 150 and 50 patients in the pulmonary and extrapulmonary ARDS groups, respectively. The two groups showed no significant differences in any assessment parameters except the serum lactate dehydrogenase (LDH) level, which was higher in the extrapulmonary ARDS group (P=0.01). After adjustment for potentially confounding covariates, there were no significant differences in 60-day mortality (P=0.99) and the duration of ventilation (P=0.45) between the two groups. Mortality was significantly associated with the disseminated intravascular coagulation (DIC) score, high-resolution computed tomography (HRCT) score, and serum LDH level in the pulmonary ARDS group and the DIC score and HRCT score in the extrapulmonary ARDS group.
Pulmonary and extrapulmonary ARDS may be comparable in terms of the prognosis and duration of ventilation. DIC and HRCT scores may be common clinical predictors of mortality with ARDS.
尽管据报道急性呼吸窘迫综合征(ARDS)表现出具有不同风险和预后因素的多种临床表型,但很少有研究评估肺源性和非肺源性ARDS的临床特征及预后。本研究的目的是调查肺源性和非肺源性ARDS之间的临床差异。
总共纳入了200例符合柏林标准且在2004年10月至2017年9月期间被诊断为ARDS的患者。我们将患者分为肺源性和非肺源性ARDS组。对两组患者进行了60天死亡率、通气时间及其他临床特征的评估。
肺源性和非肺源性ARDS组分别有150例和50例患者。除血清乳酸脱氢酶(LDH)水平外,两组在任何评估参数上均无显著差异,非肺源性ARDS组的血清LDH水平更高(P = 0.01)。在对潜在的混杂协变量进行调整后,两组之间的60天死亡率(P = 0.99)和通气时间(P = 0.45)无显著差异。在肺源性ARDS组中,死亡率与弥散性血管内凝血(DIC)评分、高分辨率计算机断层扫描(HRCT)评分及血清LDH水平显著相关;在非肺源性ARDS组中,死亡率与DIC评分和HRCT评分显著相关。
肺源性和非肺源性ARDS在预后和通气时间方面可能具有可比性。DIC和HRCT评分可能是ARDS死亡率的常见临床预测指标。